KRAS changes in pancreatic cancer
KRAS is a gene involved in controlling cell growth. Changes in this gene are common in pancreatic cancer and may appear on a tumour-testing report. The exact change can matter when discussing targeted treatments or clinical trials — and a KRAS result alone does not determine your treatment plan.
If you have been diagnosed with pancreatic cancer in Canada, KRAS may appear in your tumour-testing report — sometimes as a single line among many results. This guide explains what KRAS is, what the exact wording of a result means, and what a result may or may not change. It is written to help you have a clearer conversation with your care team.
On this page: What KRAS does · Understanding your exact result · Does a KRAS finding run in families? · What the result may — and may not — change · Could this finding affect treatment? · Questions to take to your appointment
What does KRAS do?
KRAS is a gene. It provides instructions for a protein that helps control how cells grow and divide. In a healthy cell, that protein switches growth signals on and off as needed.
Certain changes in the KRAS gene can leave the growth signalling switched on more than it should be, so cells grow and divide out of control. Changes like this are very common in pancreatic cancer: the Canadian Cancer Society notes that around 90% of pancreatic cancers have KRAS mutations.
Understanding your exact result: G12D, G12V, G12R, G12C
Labels such as G12D, G12V, G12R, and G12C identify different changes in the KRAS protein. G12D is the most common variant found in pancreatic cancer. Medicines and clinical trials may target particular variants, or broader groups of RAS changes, so the exact wording of your report matters.
A variant label is not a prognosis. On its own, it does not tell you how your cancer will behave, and this guide does not rate variants by how "targetable" they are — those judgments change quickly and belong in a conversation with your team, based on your full report.
| Report wording | What to ask |
|---|---|
| A specific KRAS variant (for example, G12D) | Does the exact variant affect any treatment or trial discussion? |
| KRAS wild-type | What other relevant findings were assessed? |
| No usable result, or an incomplete report | Was testing technically successful, and is further assessment appropriate? |
Does a KRAS finding mean this runs in my family?
Generally, no. The KRAS finding discussed in this guide is a change found in the tumour itself. A tumour finding is not, by itself, evidence of inherited pancreatic cancer risk, and it does not mean your relatives carry the same change.
Tumour testing and inherited (germline) testing answer different questions. Tumour testing looks for changes in the cancer that may affect treatment discussions. Inherited testing looks for changes you were born with, which can affect your own treatment and your family's risk. The samples differ too — tumour testing usually uses tumour tissue, while inherited testing usually uses blood or saliva — but the purpose is the important distinction, and some people will have a reason to discuss both.
Questions worth asking:
- Which test identified this result?
- Is this a tumour finding or an inherited finding?
- Have I also had the inherited testing appropriate to my diagnosis?
- Who will explain the full report?
Our guide to genetic testing for pancreatic cancer explains inherited testing in more detail.
What the result may — and may not — change
A KRAS result alone does not determine your treatment plan. It may matter when your team discusses certain targeted treatments, whether a clinical trial is worth considering, and how your cancer is understood. Many treatment decisions will not turn on the KRAS result at all.
"KRAS wild-type" means the test did not identify a KRAS mutation. This does not mean the tumour is normal or that no treatment options exist. Your team should interpret the full report and the eligibility criteria for any proposed treatment or trial. Do not infer eligibility — or ineligibility — from that label alone.
Tumours without a KRAS change are somewhat more likely to have other findings that matter for treatment, which is another reason the full report — not one line of it — is what counts. Our guide to biomarker testing explains what a full tumour-testing report can include.
Could this finding affect treatment?
Research and treatment access are changing quickly. For each medicine, distinguish the evidence, the country's regulatory decision, and the access arrangements that apply in Canada. Those are three different things, and a medicine can sit in very different positions on each:
- A medicine with an established, authorized indication in a particular country.
- A medicine being considered outside its authorized indication.
- A treatment available only through a clinical trial.
Daraxonrasib — the current example
Daraxonrasib (research code RMC-6236) is a RAS inhibitor designed to act on multiple RAS proteins, including several KRAS variants. It has phase III evidence in metastatic pancreatic cancer, and on August 26, 2026, the U.S. Food and Drug Administration approved it for metastatic pancreatic cancer in the United States.
That approval is a United States decision. Daraxonrasib is not approved in Canada, and approval in another country does not by itself create Canadian access or public funding. Our maintained article explains the Canadian position and is checked and updated as it changes: Is Daraxonrasib available in Canada? (Canadian status checked October 28, 2026.)
G12C inhibitors — a bounded example
Sotorasib and adagrasib are KRAS G12C inhibitors first approved in 2021 in the United States — for certain lung cancers. G12C accounts for only a small share of pancreatic cancers, and approval for lung cancer does not make a medicine an approved pancreatic cancer treatment. In pancreatic cancer, these medicines are being studied in clinical trials.
Whether any trial is open, recruiting, and has a place available can only be confirmed with the trial site itself; a database listing cannot confirm a place. Our guide to planning ahead for clinical trials explains how to check. Researchers are also studying why cancers respond differently to these medicines and how resistance develops — one reason combinations and additional treatment approaches are being investigated.
Questions to take to your appointment
A molecular report can contain unfamiliar terms. Ask your team to explain which findings matter now, which may be relevant later, and which do not currently change the plan. Asking these questions should not delay the treatment your team recommends starting.
- What is my exact KRAS result?
- Was the test broad enough for the question we are trying to answer?
- Does this finding affect treatment now?
- Is an appropriate trial worth considering?
- What other eligibility requirements would apply?
- Is any proposed treatment authorized and funded for my situation in Canada?
- When would it be useful to revisit the results?
Related guides
- Biomarker testing — what tumour testing covers and how results are reported.
- Genetic testing for pancreatic cancer — inherited risk and family testing.
- Treatment options — the main treatments for pancreatic cancer in Canada.
- Planning ahead for clinical trials — how trials work and how to check eligibility.
- Is Daraxonrasib available in Canada? — the maintained Canadian access article.
- Expanded clinical trial access — our advocacy for wider trial access in Canada.
Sources
- Canadian Cancer Society — Research in pancreatic cancer (KRAS explanation and the "around 90%" figure).
- U.S. National Cancer Institute — RAS research: from undruggable to new treatments (daraxonrasib evidence and U.S. approval).
This guide is general information about KRAS findings for people with pancreatic cancer in Canada, not medical advice. Treatment and trial information changes quickly; confirm current details with your care team and, for trials, directly with the trial site.
Last reviewed: October 28, 2026 · Report an error